Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database

European Urology Focus

Volumn 1, Issue 2, 2015, Pages 173-184

  Tsikkinis, Alexandros ^a   Cihoric, Nikola ^a   Giannarini, Gianluca ^b   Hinz, Stefan ^c   Briganti, Alberto ^d   Wust, Peter ^c   Ost, Piet ^e   Ploussard, Guillaume ^f   Massard, Christophe ^g   Surcel, Cristian I ^h   Sooriakumaran, Prasanna ⁱ   Isbarn, Hendrik ^j   De Visschere, Peter J L ^e   Futterer, Jurgen J ^k   van der Bergh, Roderick C N ^l   Dal Pra, Alan ^a   Aebersold, Daniel M ^a   Budach, Volker ^c   Ghadjar, Pirus ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF UDINE   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f SAINT LOUIS HOSPITAL   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h FUNDENI CLINICAL INSTITUTE   (Romania)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j Prostate Cancer Center   (Germany)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

ClinicalTrials.gov; Prospective; Prostate cancer; Trials

Indexed keywords

ABIRATERONE ACETATE; APALUTAMIDE; BICALUTAMIDE; CABAZITAXEL; CABOZANTINIB; CUSTIRSEN; DEGARELIX; DENOSUMAB; DOCETAXEL; DUTASTERIDE; ENZALUTAMIDE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; MITOXANTRONE; ORTERONEL; PREDNISONE; RADIUM CHLORIDE RA 223; STRONTIUM 89; TASQUINIMOD; TRIPTORELIN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CLINICAL EFFECTIVENESS; CLINICAL STUDY; DRUG EFFICACY; FACTUAL DATABASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 84960363663     PISSN: None     EISSN: 24054569     Source Type: Journal    
DOI: 10.1016/j.euf.2015.05.003     Document Type: Article

References (7)

1. Hirsch B.R., Califf R.M., Cheng S.K., et al. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. JAMA Intern Med 2013, 173:972-979.
2. Fizazi K., Abrahamsson P.A., Ahlgren G., et al. Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol 2015, 67:904-912.
3. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159. Prostate Cancer Clinical Trials Working Group.
4. Schwartz L.M., Woloshin S., Fowler F.J., Welch H.G. Enthusiasm for cancer screening in the United States. JAMA. 2004, 291:71-78.
5. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014, 384:2027-2035.
6. Kuban D.A., Levy L.B., Cheung M.R., et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?. Int J Radiat Oncol Biol Phys 2011, 79:1310-1317.
7. Giannarini G., Gandaglia G., Montorsi F., Briganti A. Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer?. J Clin Oncol 2014, 32:1299-1301.